Inclusion-body myositis associated with ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Inclusion-body myositis associated with Sjögren's disease: clinical characteristics and comparison with other Sjögren-associated myositis.
Auteur(s) :
Astouati, Quentin [Auteur]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
MACHET, THOMAS [Auteur]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Houssais, C. [Auteur]
Noury, J. B. [Auteur]
Lymphocytes B, Autoimmunité et Immunothérapies [LBAI]
Université de Brest [UBO]
Allenbach, Y. [Auteur]
Centre de recherche en Myologie – U974 SU-INSERM
Gallay, L. [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Quere, B. [Auteur]
Université de Brest [UBO]
Assan, F. [Auteur]
Benveniste, O. [Auteur]
Centre de recherche en Myologie – U974 SU-INSERM
Broner, J. [Auteur]
Duffau, P. [Auteur]
Université de Bordeaux [UB]
Aquitaine’s Care and Research organisation for inflammatory and Immune-Mediated diseases [CHU Bordeaux] [FHU ACRONIM]
Espitia, A. [Auteur]
Grasland, A. [Auteur]
Université Sorbonne Paris Cité [USPC]
Hayem, G. [Auteur]
Guern, V. L. [Auteur]
Martis, N. [Auteur]
Mariampillai, K. [Auteur]
Centre de recherche en Myologie – U974 SU-INSERM
Nocturne, G. [Auteur]
AP-HP. Université Paris Saclay
Mariette, X. [Auteur]
Université Paris-Saclay
Meyer, A. [Auteur]
Mulleman, D. [Auteur]
Université de Tours [UT]
Devauchelle-Pensec, V. [Auteur]
Lymphocytes B, Autoimmunité et Immunothérapies [LBAI]
Université de Brest [UBO]
Collet, Aurore [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Launay, David [Auteur]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Hachulla, Eric [Auteur]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Cornec, D. [Auteur]
Lymphocytes B, Autoimmunité et Immunothérapies [LBAI]
Université de Brest [UBO]
Guellec, D. [Auteur]
Lymphocytes B, Autoimmunité et Immunothérapies [LBAI]
Université de Brest [UBO]
Sanges, Sébastien [Auteur]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
MACHET, THOMAS [Auteur]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Houssais, C. [Auteur]
Noury, J. B. [Auteur]
Lymphocytes B, Autoimmunité et Immunothérapies [LBAI]
Université de Brest [UBO]
Allenbach, Y. [Auteur]
Centre de recherche en Myologie – U974 SU-INSERM
Gallay, L. [Auteur]
Université Claude Bernard Lyon 1 [UCBL]
Quere, B. [Auteur]
Université de Brest [UBO]
Assan, F. [Auteur]
Benveniste, O. [Auteur]
Centre de recherche en Myologie – U974 SU-INSERM
Broner, J. [Auteur]
Duffau, P. [Auteur]
Université de Bordeaux [UB]
Aquitaine’s Care and Research organisation for inflammatory and Immune-Mediated diseases [CHU Bordeaux] [FHU ACRONIM]
Espitia, A. [Auteur]
Grasland, A. [Auteur]
Université Sorbonne Paris Cité [USPC]
Hayem, G. [Auteur]
Guern, V. L. [Auteur]
Martis, N. [Auteur]
Mariampillai, K. [Auteur]
Centre de recherche en Myologie – U974 SU-INSERM
Nocturne, G. [Auteur]
AP-HP. Université Paris Saclay
Mariette, X. [Auteur]
Université Paris-Saclay
Meyer, A. [Auteur]
Mulleman, D. [Auteur]
Université de Tours [UT]
Devauchelle-Pensec, V. [Auteur]
Lymphocytes B, Autoimmunité et Immunothérapies [LBAI]
Université de Brest [UBO]
Collet, Aurore [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Launay, David [Auteur]

Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Hachulla, Eric [Auteur]

Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Cornec, D. [Auteur]
Lymphocytes B, Autoimmunité et Immunothérapies [LBAI]
Université de Brest [UBO]
Guellec, D. [Auteur]
Lymphocytes B, Autoimmunité et Immunothérapies [LBAI]
Université de Brest [UBO]
Sanges, Sébastien [Auteur]

Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Titre de la revue :
Rheumatology
Nom court de la revue :
Rheumatology (Oxford)
Date de publication :
2024-03-01
ISSN :
1462-0332
Résumé en anglais : [en]
Objectives
To describe the characteristics of patients with Sjögren’s disease (SjD) and inclusion-body myositis (IBM), and how they compare to SjD patients with other inflammatory myopathies (IM).
Methods
Patients ...
Lire la suite >Objectives To describe the characteristics of patients with Sjögren’s disease (SjD) and inclusion-body myositis (IBM), and how they compare to SjD patients with other inflammatory myopathies (IM). Methods Patients were retrospectively recruited from 13 French centres and included if they met the ACR/EULAR criteria for SjD and for IM. They were categorized as SjD-IBM if sub-criteria for IBM were met, or as SjD-other IM if not. Results SjD-IBM patients (n = 22) were mostly females (86%), with a median [Q1; Q3] age of 54 [38.5; 64] years at SjD diagnosis, and 62 [46.5; 70] years at first IBM symptoms. Although most patients displayed glandular and immunological abnormalities, additional extra-glandular manifestations were uncommon, resulting in moderate disease activity at SjD diagnosis (ESSDAI 5.5 [1; 7.8]). Classic IBM features were frequent, such as progressive symptom onset (59%), asymmetrical (27%) and distal (32%) involvements, dysphagia (41%), low CPK (386.5 [221.8; 670.5] UI/l) and CRP (3.0 [3; 8.5] mg/l) levels. Immunosuppressants were reported as efficient in 55% of cases. Compared with SjD-IBM patients, SjD patients with other IM (n = 50) were significantly younger, displayed more frequent additional extra-glandular disease, higher ESSDAI score (11 [3; 30]), shorter delay between SjD diagnosis and myositis onset (0 [−0.5; 26]), more frequent CPK values over 1000 UI/l (36%), and less frequent classic IBM features. Conclusion IBM can occur in SjD patients, with muscle features reminiscent of classic sporadic IBM characteristics, but mostly affecting women. In SjD patients with muscle involvement, extra-glandular manifestations, high ESSDAI score, elevated CPK values and shorter delay after SjD diagnosis plead against IBM.Lire moins >
Lire la suite >Objectives To describe the characteristics of patients with Sjögren’s disease (SjD) and inclusion-body myositis (IBM), and how they compare to SjD patients with other inflammatory myopathies (IM). Methods Patients were retrospectively recruited from 13 French centres and included if they met the ACR/EULAR criteria for SjD and for IM. They were categorized as SjD-IBM if sub-criteria for IBM were met, or as SjD-other IM if not. Results SjD-IBM patients (n = 22) were mostly females (86%), with a median [Q1; Q3] age of 54 [38.5; 64] years at SjD diagnosis, and 62 [46.5; 70] years at first IBM symptoms. Although most patients displayed glandular and immunological abnormalities, additional extra-glandular manifestations were uncommon, resulting in moderate disease activity at SjD diagnosis (ESSDAI 5.5 [1; 7.8]). Classic IBM features were frequent, such as progressive symptom onset (59%), asymmetrical (27%) and distal (32%) involvements, dysphagia (41%), low CPK (386.5 [221.8; 670.5] UI/l) and CRP (3.0 [3; 8.5] mg/l) levels. Immunosuppressants were reported as efficient in 55% of cases. Compared with SjD-IBM patients, SjD patients with other IM (n = 50) were significantly younger, displayed more frequent additional extra-glandular disease, higher ESSDAI score (11 [3; 30]), shorter delay between SjD diagnosis and myositis onset (0 [−0.5; 26]), more frequent CPK values over 1000 UI/l (36%), and less frequent classic IBM features. Conclusion IBM can occur in SjD patients, with muscle features reminiscent of classic sporadic IBM characteristics, but mostly affecting women. In SjD patients with muscle involvement, extra-glandular manifestations, high ESSDAI score, elevated CPK values and shorter delay after SjD diagnosis plead against IBM.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Date de dépôt :
2024-03-05T22:00:38Z
2024-07-11T13:24:28Z
2024-07-11T13:24:28Z